Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank57
3Y CAGR-10.2%
5Y CAGR-3.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-10.2%/yr
vs +31.4%/yr prior
5Y CAGR
-3.6%/yr
Recent deceleration
Acceleration
-41.6pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
3 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$105.21M-8.9%
2024$115.44M-12.5%
2023$131.88M-9.3%
2022$145.40M+1.1%
2021$143.85M+13.8%
2020$126.42M+19.9%
2019$105.42M+115.8%
2018$48.85M+96.4%
2017$24.87M+3.9%
2016$23.95M-